These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15361643)

  • 1. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
    Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
    Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
    Mamon HJ; Niedzwiecki D; Hollis D; Tan BR; Mayer RJ; Tepper JE; Goldberg RM; Blackstock AW; Fuchs CS;
    Cancer; 2011 Jun; 117(12):2620-8. PubMed ID: 21656739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2.
    Hatoum H; Rosemurgy A; Bastidas JA; Zervos E; Muscarella P; Edil BH; Cynamon J; Johnson DT; Thomas C; Swinson BM; Nordgren A; Vitulli P; Nutting C; Gipson M; Tsobanoudis A; Agah R
    Oncologist; 2024 Aug; 29(8):690-698. PubMed ID: 39049803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
    Burris HA; Moore MJ; Andersen J; Green MR; Rothenberg ML; Modiano MR; Cripps MC; Portenoy RK; Storniolo AM; Tarassoff P; Nelson R; Dorr FA; Stephens CD; Von Hoff DD
    J Clin Oncol; 1997 Jun; 15(6):2403-13. PubMed ID: 9196156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
    Arnoletti JP; Frolov A; Eloubeidi M; Keene K; Posey J; Wood T; Greeno E; Jhala N; Varadarajulu S; Russo S; Christein J; Oster R; Buchsbaum DJ; Vickers SM
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):891-7. PubMed ID: 20589377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).
    Berlin JD; Feng Y; Catalano P; Abbruzzese JL; Philip PA; McWilliams RR; Lowy AM; Benson AB; Blackstock AW
    Oncology; 2018; 94(1):39-46. PubMed ID: 29040974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine therapy in patients with advanced pancreatic cancer.
    Min YJ; Joo KR; Park NH; Yun TK; Nah YW; Nam CW; Park JH
    Korean J Intern Med; 2002 Dec; 17(4):259-62. PubMed ID: 12647642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer.
    Rezaee M; Wang J; Razavi M; Ren G; Zheng F; Hussein A; Ullah M; Thakor AS
    Sci Rep; 2019 Nov; 9(1):15929. PubMed ID: 31685925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
    Attia S; Kolesar J; Mahoney MR; Pitot HC; Laheru D; Heun J; Huang W; Eickhoff J; Erlichman C; Holen KD
    Invest New Drugs; 2008 Aug; 26(4):369-79. PubMed ID: 18278438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
    Plate JM; Plate AE; Shott S; Bograd S; Harris JE
    Cancer Immunol Immunother; 2005 Sep; 54(9):915-25. PubMed ID: 15782312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.
    Rich TA; Winter K; Safran H; Hoffman JP; Erickson B; Anne PR; Myerson RJ; Cline-Burkhardt VJ; Perez K; Willett C
    Onco Targets Ther; 2012; 5():161-70. PubMed ID: 22977306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.
    Burris HA; Moore MJ; Andersen J; Green MR; Rothenberg ML; Modiano MR; Cripps MC; Portenoy RK; Storniolo AM; Tarassoff P; Nelson R; Dorr FA; Stephens CD; Von Hoff DD
    J Clin Oncol; 2023 Dec; 41(36):5482-5492. PubMed ID: 38100992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
    Krishnan S; Rana V; Janjan NA; Varadhachary GR; Abbruzzese JL; Das P; Delclos ME; Gould MS; Evans DB; Wolff RA; Crane CH
    Cancer; 2007 Jul; 110(1):47-55. PubMed ID: 17538975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
    J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review.
    Huguet F; Girard N; Guerche CS; Hennequin C; Mornex F; Azria D
    J Clin Oncol; 2009 May; 27(13):2269-77. PubMed ID: 19307501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
    Saif MW
    JOP; 2008 Jul; 9(4):391-7. PubMed ID: 18648128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary Investigation of the Efficacy and Indications of Proton Beam Therapy for Stage IV Pancreatic Adenocarcinoma.
    Yamaguchi H; Kato T; Narita Y; Honda M; Hamada K; Ishikawa Y; Seto I; Takagawa Y; Kikuchi Y; Murakami M
    Cureus; 2024 Apr; 16(4):e57771. PubMed ID: 38716033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic Cancer: Feasibility and Outcome After Radiochemotherapy with High Dose External Radiotherapy for Non-resected and R1 Resected Patients.
    Lauffer DC; Kuhn PA; Kueng M; Thalmann SU; Risse G; Tercier PA; Egger B; Allal AS
    Cureus; 2018 May; 10(5):e2713. PubMed ID: 30079279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
    Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
    J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.